LY3499446 + Abemaciclib + Cetuximab + Erlotinib + Docetaxel
Phase 1/2Terminated 0 watching 0 views this week⚡ Active
41
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Advanced Solid Tumor
Conditions
Advanced Solid Tumor, Non-Small Cell Lung Cancer, Colorectal Cancer
Trial Timeline
Nov 28, 2019 → Oct 30, 2020
NCT ID
NCT04165031About LY3499446 + Abemaciclib + Cetuximab + Erlotinib + Docetaxel
LY3499446 + Abemaciclib + Cetuximab + Erlotinib + Docetaxel is a phase 1/2 stage product being developed by Eli Lilly for Advanced Solid Tumor. The current trial status is terminated. This product is registered under clinical trial identifier NCT04165031. Target conditions include Advanced Solid Tumor, Non-Small Cell Lung Cancer, Colorectal Cancer.
Hype Score Breakdown
Clinical
13
Activity
8
Company
10
Novelty
4
Community
3
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04165031 | Phase 1/2 | Terminated |
Competing Products
20 competing products in Advanced Solid Tumor
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| AK-105 | Akeso | Phase 1 | 32 |
| AFM24 + Atezolizumab 840 MG in 14 ML Injection | Affimed | Phase 1/2 | 33 |
| EXS21546 | Biotrial | Phase 1/2 | 33 |
| SY-1365 (Part 1) + Carboplatin + Fulvestrant + SY-1365 (Cohort 2) + SY-1365 (Cohort 5) + SY-1365 (Part 2 Single Agent) | Syros Pharmaceuticals | Phase 1 | 25 |
| Necitumumab + Gemcitabine + Carboplatin | Eli Lilly | Phase 2 | 52 |
| Pemetrexed + Erlotinib + Pemetrexed + Erlotinib | Eli Lilly | Phase 2 | 52 |
| NBTXR3 | Nanobiotix | Phase 1/2 | 36 |
| pegfilgrastim + LY2523355 | Eli Lilly | Phase 1 | 33 |
| SON-1010 | Sonnet BioTherapeutics | Phase 1 | 28 |
| SON-1010 | Sonnet BioTherapeutics | Phase 1/2 | 36 |
| BT1718 | Bicycle Therapeutics | Phase 1/2 | 33 |
| Zentalis + Gemzar | Zentalis Pharmaceuticals | Phase 2 | 44 |
| IMC-18F1 | Eli Lilly | Phase 1 | 33 |
| Tadalafil + Gemcitabine | Eli Lilly | Phase 1 | 33 |
| OKI-179 | OnKure Therapeutics | Phase 1 | 25 |
| OKI-219 + Fulvestrant + Trastuzumab + Tucatinib + Atirmociclib + Ribociclib | OnKure Therapeutics | Phase 1 | 25 |
| LY3434172 | Eli Lilly | Phase 1 | 33 |
| ACR-2316 | Acrivon Therapeutics | Phase 1 | 25 |
| BBP-398 | LianBio | Phase 1 | 25 |
| LY3200882 + Pembrolizumab | Eli Lilly | Phase 1/2 | 41 |